LB Pharmaceuticals Statistics
Total Valuation
LBRX has a market cap or net worth of $354.15 million. The enterprise value is $353.11 million.
| Market Cap | 354.15M |
| Enterprise Value | 353.11M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
LBRX has 22.44 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Current Share Class | 22.44M |
| Shares Outstanding | 22.44M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.48% |
| Owned by Institutions (%) | 7.34% |
| Float | 21.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 35.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.78, with a Debt / Equity ratio of 0.36.
| Current Ratio | 3.78 |
| Quick Ratio | 3.64 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -209.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.84M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LBRX has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,246,383 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.21M |
| Pretax Income | -29.43M |
| Net Income | -29.43M |
| EBITDA | -31.97M |
| EBIT | -32.21M |
| Earnings Per Share (EPS) | -$116.88 |
Balance Sheet
The company has $14.23 million in cash and $3.76 million in debt, giving a net cash position of $10.46 million or $0.47 per share.
| Cash & Cash Equivalents | 14.23M |
| Total Debt | 3.76M |
| Net Cash | 10.46M |
| Net Cash Per Share | $0.47 |
| Equity (Book Value) | 10.39M |
| Book Value Per Share | -412.54 |
| Working Capital | 10.88M |
Cash Flow
In the last 12 months, operating cash flow was -$41.43 million and capital expenditures -$693,000, giving a free cash flow of -$42.13 million.
| Operating Cash Flow | -41.43M |
| Capital Expenditures | -693,000 |
| Free Cash Flow | -42.13M |
| FCF Per Share | -$1.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | -0.87% |
| Earnings Yield | -8.09% |
| FCF Yield | -11.59% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |